Elevation Oncology, Inc. (ELEV)
NASDAQ: ELEV · Real-Time Price · USD
0.2598
-0.0002 (-0.08%)
Mar 31, 2025, 10:59 AM EDT - Market open

Elevation Oncology Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
16.1114.915.838.451.8
Upgrade
Research & Development
28.625.4378.7223.615.48
Upgrade
Operating Expenses
44.740.3494.5532.0517.28
Upgrade
Operating Income
-44.7-40.34-94.55-32.05-17.28
Upgrade
Interest Expense
-4-4.13-1.5--
Upgrade
Interest & Investment Income
5.23.91--
Upgrade
Other Non Operating Income (Expenses)
---0.010.010.01
Upgrade
EBT Excluding Unusual Items
-43.5-40.57-95.06-32.04-17.27
Upgrade
Merger & Restructuring Charges
--5.11---
Upgrade
Other Unusual Items
-0.94----
Upgrade
Pretax Income
-44.44-45.67-95.06-32.04-17.27
Upgrade
Income Tax Expense
0.040.030.03--
Upgrade
Net Income
-44.49-45.7-95.08-32.04-17.27
Upgrade
Net Income to Common
-44.49-45.7-95.08-32.04-17.27
Upgrade
Shares Outstanding (Basic)
573723121
Upgrade
Shares Outstanding (Diluted)
573723121
Upgrade
Shares Change (YoY)
56.82%56.97%91.77%1432.24%6.43%
Upgrade
EPS (Basic)
-0.78-1.25-4.09-2.64-21.80
Upgrade
EPS (Diluted)
-0.78-1.25-4.09-2.64-21.80
Upgrade
Free Cash Flow
-36.36-56.18-85.57-30.17-12.37
Upgrade
Free Cash Flow Per Share
-0.64-1.54-3.68-2.49-15.62
Upgrade
EBITDA
-44.68-40.3-94.52-32.03-
Upgrade
D&A For EBITDA
0.020.040.030.02-
Upgrade
EBIT
-44.7-40.34-94.55-32.05-17.28
Upgrade
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q